ReviewFrontiers in pharmacology2026
Mitochondrial cristae remodeling in ischemic stroke: mechanisms and therapeutic perspectives.
Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Mitochondrial cristae arrange the respiratory machinery within the inner membrane and change as ischemia gives way to reperfusion. Their organization depends on mitochondrial contact site and cristae organizing system assemblies, optic atrophy 1, adenosine triphosphate synthase, and cardiolipin. Disruption of these systems can impair energy production, facilitate neuronal death, and expose mitochondrial DNA to inflammatory sensors. This review brings structural work together with experimental stroke studies to examine how crista remodeling contributes to injury and recovery. Genetic manipulation of selected regulators has preserved mitochondrial structure and reduced injury in neurons and microglia. Most of these interventions preceded ischemia, leaving the speed and feasibility of repair after stroke onset uncertain. Pharmacological modulation and mitochondrial delivery offer ways to address this gap, particularly around reperfusion. Emerging strategies combine modulation of crista protein assemblies with cardiolipin directed treatment, mitochondrial antioxidant nanomedicine, organelle delivery, and control of local drug exposure. Their therapeutic evaluation can be aligned with distinct opportunities at reperfusion and during subsequent tissue recovery. Progress toward treatment will require evidence that a candidate reaches the affected brain cells, modifies the intended membrane assembly, and produces lasting neurological benefit. The available studies place crista remodeling within neuroprotective pathways and identify the experimental steps needed to evaluate it as a therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.